Contribute Try STAT+ Today

Good morning, everyone, and how are you today? We are doing just fine, thank you, now that the Pharmalot campus has settled down. The short person is hunched over the laptop for another day of remote learning and the official mascot is finally starting to snooze after a long constitutional. All of which means that we can focus on the matters at hand — brewing cups of stimulation and foraging for items of interest. On that note, here is the latest menu of tidbits to get you started. Hope that all goes well today and that you stay safe. …

The AstraZeneca (AZN) Covid-19 vaccine trial in the U.S. is expected to resume as early as this week after the Food and Drug Administration completed its review of a serious illness in a study participant, Reuters reports. The trial has been on hold since Sept. 6, after a participant in the company’s UK trial fell ill with what was suspected to be a rare spinal inflammatory disorder called transverse myelitis. It was unclear how the FDA would characterize the illness.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • While Lilly is correct to say they have not yet received a warning letter for the issues at their NJ facility, may one observe that those letters often take over a year for a domestic facility? Add the second 483 and one wonders if a rewrite is in process, or not. “Time will tell.”

Comments are closed.

Your daily dose of news in health and medicine

Privacy Policy